Journal Article

Cryoballoon Pulmonary Vein Isolation as First-Line Treatment for Typical Atrial Flutter

Clarkson, Nichola, Kemp, Ian, Gupta, Dhiraj, Morgan, Maureen, Barton, Janet, Tovmassian, Lilith, Rajappan, Kim, Ding, Wern Yew, Williams, Emmanuel, Reichlin, Tobias, Ronayne, Christina, Sticherling, Christian, Temple, Ian Peter, Haywood, Guy, Tayebjee, Muzahir H, Martin, Claire A, Calvert, Peter, Balasubramaniam, Richard N, Mahida, Saagar, Chen, Zhong, Bates, Matthew G D, Das, Moloy

2023

Overview

ObjectiveWe aimed to compare cryoballoon pulmonary vein isolation (PVI) with standard radiofrequency cavotricuspid isthmus (CTI) ablation as first-line treatment for typical atrial flutter (AFL).MethodsCryoballoon Pulmonary Vein Isolation as First-Line Treatment for Typical Atrial Flutter was an international, multicentre, open with blinded assessment trial. Patients with CTI-dependent AFL and no documented atrial fibrillation (AF) were randomised to either cryoballoon PVI alone or radiofrequency CTI ablation. Primary efficacy outcome was time to first recurrence of sustained (>30 s) symptomatic atrial arrhythmia (AF/AFL/atrial tachycardia) at 12 months as assessed by continuous monitoring with an implantable loop recorder. Primary safety outcome was a composite of death, stroke, tamponade requiring drainage, atrio-oesophageal fistula, pacemaker implantation, serious vascular complications or persistent phrenic nerve palsy.ResultsTrial recruitment was halted at 113 of the target 130 patients because of the SARS-CoV-2 pandemic (PVI, n=59; CTI ablation, n=54). Median age was 66 (IQR 61–71) years, with 98 (86.7%) men. At 12 months, the primary outcome occurred in 11 (18.6%) patients in the PVI group and 9 (16.7%) patients in the CTI group. There was no significant difference in the primary efficacy outcome between the groups (HR 1.11, 95% CI 0.46 to 2.67). AFL recurred in six (10.2%) patients in the PVI arm and one (1.9%) patient in the CTI arm (p=0.116). Time to occurrence of AF of ≥2 min was significantly reduced with cryoballoon PVI (HR 0.46, 95% CI 0.25 to 0.85). The composite safety outcome occurred in four patients in the PVI arm and three patients in the CTI arm (p=1.000).ConclusionCryoballoon PVI as first-line treatment for AFL is equally effective compared with standard CTI ablation for preventing recurrence of atrial arrhythmia and better at preventing new-onset AF.Trial registration number NCT03401099.

• Publisher: BMJ Publishing Group Ltd and British Cardiovascular Society,BMJ Publishing Group LTD
• Subject: Ablation / Ablation Techniques / Aged / Arrhythmias and sudden death / Arrhythmias, Cardiac / Atrial Fibrillation / Atrial Fibrillation - diagnosis / Atrial Fibrillation - epidemiology / Atrial Fibrillation - surgery / Atrial Flutter / Atrial Flutter - diagnosis / Atrial Flutter - epidemiology / Atrial Flutter - surgery / Cardiac arrhythmia / Cardioversion / Catheter Ablation / Catheter Ablation - adverse effects / Catheters / COVID-19 - complications / Female / Fistula / Humans / Male / Neurological disorders / Pacemakers / Pulmonary Veins - surgery / Quality of life / Questionnaires / Recurrence / SARS-CoV-2 / Stroke / Tachycardia, Supraventricular / Transient ischemic attack / Treatment Outcome / Veins & arteries